GENB
Financial ServicesGenerate Biomedicines, Inc. · Asset Management · $2B
What is Generate Biomedicines, Inc.?
Generate Biomedicines is a clinical-stage biotechnology company applying machine learning to protein drug discovery. Based in Somerville, Massachusetts, it aims to design novel protein therapeutics that go beyond what traditional drug development methods can achieve.
Generate Biomedicines uses its proprietary Generate Platform — a system combining computational biology with scalable biohardware — to design protein-based medicines. The company earns no product revenue yet; it advances a pipeline of investigational therapies through clinical development, funded by capital raises rather than commercial sales. Its approach targets diseases where conventional biologics have struggled to deliver durable solutions.
The company was incorporated in 2018 and is headquartered in Somerville, Massachusetts.
- GB-0895 — investigational long-acting anti-TSLP antibody for severe asthma, designed for twice-yearly dosing
- GB-4362 — monoclonal antibody targeting MMAE payload neutralization
- GB-5267 — MUC16-directed CAR-T cell therapy in development
- Generate Platform — modality-agnostic computational and biohardware drug design system
Is GENB a Good Stock to Buy?
UQS Score rates GENB as Poor overall, reflecting the early-stage nature of the business across most evaluated dimensions.
The one area where GENB stands out relative to its profile is Risk, which is rated Good — suggesting the company's balance sheet or near-term financial exposure is managed better than its overall score might imply.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue biotech that has yet to establish commercial products or durable competitive advantages. Valuation is rated Elevated, meaning the current price reflects significant future expectations.
See the complete pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GENB pay dividends?
No — Generate Biomedicines, Inc. does not currently pay a dividend.
Generate Biomedicines does not pay a dividend. As a pre-revenue clinical-stage company, available capital is directed toward research, platform development, and advancing its therapeutic pipeline — not shareholder distributions. Income-focused investors should factor this into their assessment.
When does GENB report earnings?
Generate Biomedicines reports financial results on a quarterly cadence, standard for US-listed companies.
As a pre-revenue biotech, quarterly reports focus on pipeline progress, cash runway, and operating expenses rather than sales or profit metrics. Investors typically watch for clinical trial updates and platform milestones alongside the financial statements.
For the most current results and disclosures, visit Generate Biomedicines' official investor relations page.
GENB Price History
+0.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
GENB Long-term Outlook
With Growth and Quality both rated Weak, GENB's near-term fundamental trajectory depends heavily on clinical trial outcomes rather than organic business momentum. The Good Risk rating provides some reassurance about financial stability in the short run, but the Elevated Valuation rating suggests the market has already priced in optimistic pipeline scenarios. Execution risk remains the dominant variable.
Growth drivers
- Advancement of GB-0895 through clinical trials for severe asthma, a large and underserved patient population
- Broader application of the Generate Platform across additional therapeutic areas and protein modalities
- Potential partnership or licensing deals that could validate the platform and provide non-dilutive capital
Key risks
- Clinical failure of lead pipeline assets, which would materially impair the investment case
- Elevated valuation leaves limited margin of safety if development timelines extend
- Ongoing cash consumption without product revenue creates dependence on capital markets
GENB vs Peers
GENB is listed alongside the following companies in its peer group on UQS Score — though their business models differ meaningfully from Generate Biomedicines' biotech focus.
Guardian Capital is a diversified financial services firm managing institutional and retail assets, operating in a fundamentally different industry from clinical-stage drug development.
Central Securities is a closed-end investment fund with a long-standing equity portfolio, contrasting sharply with GENB's pre-revenue biotech model.
United Corporations is a Canadian holding company with diversified investment interests, representing a capital-preservation profile quite distinct from GENB's high-risk pipeline focus.
Frequently Asked Questions
What does Generate Biomedicines do?
Generate Biomedicines uses machine learning and a proprietary computational platform to design novel protein-based medicines. Its pipeline includes investigational therapies for severe asthma, oncology, and other conditions where traditional drug development has faced limitations.
Does GENB pay dividends?
No. Generate Biomedicines does not pay a dividend. The company is pre-revenue and reinvests all available capital into research and pipeline development. A dividend is unlikely until the business reaches commercial-stage operations.
When does GENB report earnings?
Generate Biomedicines follows a standard quarterly reporting schedule. Because it is pre-revenue, reports center on pipeline updates and cash position rather than sales figures. Check the company's investor relations page for the latest schedule.
Is GENB a good stock to buy?
UQS Score rates GENB as Poor overall. The Quality, Moat, and Growth pillars are all Weak, while Valuation is Elevated. The Good Risk rating is a relative positive. Investors should weigh the clinical-stage risk profile carefully before forming a view.
Is GENB overvalued?
The UQS Valuation pillar for GENB is rated Elevated, indicating the current market price reflects ambitious expectations for pipeline success. Pre-revenue biotechs often trade on future potential, which can leave limited downside protection if trials disappoint.
How does GENB compare to its competitors?
The peer group assigned to GENB on UQS Score includes financial holding companies and investment funds, which differ substantially from a clinical-stage biotech. Direct comparisons are limited; GENB is better evaluated against other early-stage protein therapeutics companies.
What is GENB's market cap bracket?
Generate Biomedicines is classified as a small-cap company. This places it in a tier where liquidity can be lower and price volatility higher than large- or mega-cap peers — a relevant consideration for position sizing.
Who founded Generate Biomedicines?
Generate Biomedicines was incorporated in 2018 and was formerly known as Generate Biologics, Inc. before changing its name in February 2020. Founding details are publicly available through the company's official disclosures and SEC filings.
Is GENB a long-term quality indicator?
Based on the UQS five-pillar framework, GENB does not currently demonstrate the Quality or Moat characteristics associated with long-term durable businesses. Its long-term profile depends almost entirely on whether its clinical pipeline delivers validated results over time.
What is the main competitive advantage of Generate Biomedicines?
Generate Biomedicines' stated differentiation is its Generate Platform — a system designed to combine computational protein design with scalable biohardware. If validated, this platform could enable drug discovery across multiple therapeutic areas faster than conventional methods.
Unlock Full GENB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare GENB against sector peers on a standardized scoring framework
- ✓Track score changes over time as pipeline and financials evolve
- ✓Get the complete analyst view available exclusively to Pro members
Pro Analysis
GENB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 21.1 | 25.0 | 17.0 | 0.0 | 70.5 | 0.0 | -4.9 |
| Apr 22, 2026 | 26.0 | 25.0 | 17.0 | 24.6 | 70.5 | 0.0 | -1.2 |
| Apr 2, 2026 | 27.2 | 25.0 | 17.0 | 30.8 | 70.5 | 0.0 | — |
GENB — Pillar Breakdown
Quality
— 25.0/100 (25%)Generate Biomedicines, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 24.6/100 (20%)Generate Biomedicines, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 70.5/100 (15%)Generate Biomedicines, Inc. maintains a reasonable risk profile with manageable debt levels.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Generate Biomedicines, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 17/100 (25%)Generate Biomedicines, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GENB.
Score Composition
Financial Data
More Stock Analysis
How is the GENB UQS Score Calculated?
The UQS (Unified Quality Score) for Generate Biomedicines, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Generate Biomedicines, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Generate Biomedicines, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.